Specialty Physicians Weigh in with Opinions About the US Food and Drug Administration
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat, Ardelyx’s tenapanor, and the entire JAK inhibitor class EXTON, Pa., July 27, 2021 /PRNewswire/ — In reaction to major market events over the past several months, analysts at Spherix recently captured an increasingly negative sentiment towards the […]
As GSK, Aurinia Heat up the Lupus Nephritis Category, Analyst Gauges Doctors’ First Impressions
From: FiercePharma By: Beth Snyder Bulik The lupus nephritis category is sporting a first-ever brand battle—two new-to-category drugs with very different profiles and marketing strategies…(read more).
Early Experiences and Perceptions of Recently Approved Lupus Nephritis Products BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Begin to Drive Increased Prescribing Among Nephrologists and Rheumatologists
After several months on the market to treat lupus nephritis, uptake and prescribing patterns of Benlysta and Lupkynis reveal nephrologists and rheumatologists are approaching the new products from different perspectives EXTON, Pa., June 8, 2021 /PRNewswire/ — The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a […]
SGLT2 Inhibitors Poised to Potentially Reshape Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) Patient Care After AstraZeneca’s Farxiga Approval
According to new research from Spherix Global Insights, the FDA approval of Farxiga is likely to ignite a shift towards earlier CKD patient care with agents in the SGLT2 inhibitor class, including Invokana (Vifor/Janssen), Jardiance (Eli Lilly/Boehringer Ingelheim), and Steglatro (Merck) EXTON, Pa., / May 12, 2021 / PRNewswire – Nephrologists have long considered chronic […]
Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains largely virtual, and many practices are unlikely to return to pre-pandemic volumes EXTON, Pa., April 7, 2021 /PRNewswire/ — Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists) in the […]
Groundbreaking New Research from Spherix Global Insights Leverages More Than 1,100 Patient Charts to Provide Insights on IgA Nephropathy, Focal Segmental Glomerulosclerosis, and Alport Syndrome
Spherix announces the release of three new research publications in its RealWorld Dynamix™ series, revealing patient types, treatment paradigms, and unmet needs within IgAN, FSGS, and Alport Syndrome EXTON, Pa., March 22, 2021 /PRNewswire/ — Glomerular diseases, including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and Alport Syndrome, among others, together amount to the third […]
On the Heels of Recent FDA Approvals, GlaxoSmithKline’s BENLYSTA (belimumab) and Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) Emerge as Practical and Effective Tools in the Treatment of Lupus Nephritis
According to Spherix Global Insights, nephrologists and rheumatologists express measured optimism about these treatment options and seek more experience with the drugs EXTON, Pa., March 12, 2021 /PRNewswire/ — The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] As many as half of the […]
As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve – If at All?
According to new research published by Spherix Global Insights, the CKD non-dialysis market is poised for seismic shifts as SGLT2 inhibitors, including Invokana (Vifor (Relypsa)/Janssen), Farxiga (AstraZeneca), Jardiance (Eli Lilly/Boehringer Ingelheim), and Steglatro (Merck) embrace an expanded role in diabetic nephropathy and CKD patient care in 2021 EXTON, Pa., / March 4, 2021 / PRNewswire […]
The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry, particularly when it comes to in-person promotion EXTON, Pa., February 12, 2021 /PRNewswire/ — Ten months after the doors closed in response to the COVID-19 pandemic, a survey of 266 US specialty physicians conducted by Spherix Global […]
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) and Zeposia (BMS) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis EXTON, Pa., January 29, 2020 /PRNewswire/ —Spherix Global Insights, a […]
